Progress and Problems in Understanding and Managing Primary Epstein-Barr Virus Infections

SUMMARY Epstein-Barr virus (EBV) is a gammaherpesvirus that infects a large fraction of the human population. Primary infection is often asymptomatic but results in lifelong infection, which is kept in check by the host immune system. In some cases, primary infection can result in infectious mononucleosis. Furthermore, when host-virus balance is not achieved, the virus can drive potentially lethal lymphoproliferation and lymphomagenesis. In this review, we describe the biology of EBV and the host immune response. We review the diagnosis of EBV infection and discuss the characteristics and pathogenesis of infectious mononucleosis. These topics are approached in the context of developing therapeutic and preventative strategies.

[1]  A. Denys.  [Antiviral drugs]. , 2011, Polski merkuriusz lekarski : organ Polskiego Towarzystwa Lekarskiego.

[2]  S. Tangye,et al.  Impaired Epstein-barr Virus–specific Cd8 Ϩ T-cell Function in X-linked Lymphoproliferative Disease Is Restricted to Slam Family–positive B-cell Targets Eplpqgqltay from Bzlf1 and Yplheqhgm from Ebna3a, the B*2705- Restricted Epitopes, Rriydliel from Ebna3c, Hrcqairkk from Ebna3b, Rrrwrrltv from Lmp2 , 2022 .

[3]  V. M. Holers,et al.  Epstein-Barr virus promotes interferon-alpha production by plasmacytoid dendritic cells. , 2010, Arthritis and rheumatism.

[4]  M. Gulley,et al.  Using Epstein-Barr Viral Load Assays To Diagnose, Monitor, and Prevent Posttransplant Lymphoproliferative Disorder , 2010, Clinical Microbiology Reviews.

[5]  S. Kenney,et al.  The Epstein-Barr Virus (EBV)-Encoded Protein Kinase, EBV-PK, but Not the Thymidine Kinase (EBV-TK), Is Required for Ganciclovir and Acyclovir Inhibition of Lytic Viral Production , 2010, Journal of Virology.

[6]  H. Balfour,et al.  A method for evaluating antiviral drug susceptibility of Epstein-Barr virus , 2010 .

[7]  L. Hutt-Fletcher,et al.  Fusion of epithelial cells by Epstein–Barr virus proteins is triggered by binding of viral glycoproteins gHgL to integrins αvβ6 or αvβ8 , 2009, Proceedings of the National Academy of Sciences.

[8]  Jaap M Middeldorp,et al.  A Phase I Trial of Epstein-Barr Virus Gp350 Vaccine for Children With Chronic Kidney Disease Awaiting Transplantation , 2009, Transplantation.

[9]  H. Einsele,et al.  Outcome of treatment of Epstein–Barr virus‐related post‐transplant lymphoproliferative disorder in hematopoietic stem cell recipients: a comprehensive review of reported cases , 2009, Transplant infectious disease : an official journal of the Transplantation Society.

[10]  K. Kawa,et al.  Epstein-Barr virus (EBV)–encoded small RNA is released from EBV-infected cells and activates signaling from toll-like receptor 3 , 2009, The Journal of experimental medicine.

[11]  D. Follmann,et al.  Long-Term Administration of Valacyclovir Reduces the Number of Epstein-Barr Virus (EBV)-Infected B Cells but Not the Number of EBV DNA Copies per B Cell in Healthy Volunteers , 2009, Journal of Virology.

[12]  B. Ford,et al.  Evidence-Based Approach for Interpretation of Epstein-Barr Virus Serological Patterns , 2009, Journal of Clinical Microbiology.

[13]  S. Groshong,et al.  Murine gammaherpesvirus 68 infection of IFNgamma unresponsive mice: a small animal model for gammaherpesvirus-associated B-cell lymphoproliferative disease. , 2009, Cancer research.

[14]  J. Palefsky,et al.  EBV BMRF-2 facilitates cell-to-cell spread of virus within polarized oral epithelial cells. , 2009, Virology.

[15]  J. Cohen.  Optimal treatment for chronic active Epstein–Barr virus disease , 2009, Pediatric transplantation.

[16]  I. Anthony,et al.  Regulatory T cell activity in primary and persistent Epstein–Barr virus infection , 2009, Journal of medical virology.

[17]  J. Lünemann,et al.  Antiviral immune responses: triggers of or triggered by autoimmunity? , 2009, Nature Reviews Immunology.

[18]  J. Fox,et al.  Interlaboratory Comparison of Epstein‐Barr Virus Viral Load Assays , 2009, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[19]  R. Glaser,et al.  The EBV-Encoded dUTPase Activates NF-κB through the TLR2 and MyD88-Dependent Signaling Pathway1 , 2009, The Journal of Immunology.

[20]  D. Hughes,et al.  The Epstein–Barr Virus Genome , 2009 .

[21]  C. Jones,et al.  The EBV-encoded dUTPase activates NF-kappa B through the TLR2 and MyD88-dependent signaling pathway. , 2009, Journal of immunology.

[22]  Xia Zhang,et al.  Interleukin‐10: new perspectives on an old cytokine , 2008, Immunological reviews.

[23]  A. Moormann,et al.  Immune escape by Epstein-Barr virus associated malignancies. , 2008, Seminars in cancer biology.

[24]  F. Klauschen,et al.  SAP-controlled T-B cell interactions underlie germinal centre formation , 2008, Nature.

[25]  W. Wilson,et al.  Oropharyngeal shedding of Epstein-Barr virus in the absence of circulating B cells. , 2008, The Journal of infectious diseases.

[26]  M. Putukian,et al.  Mononucleosis and Athletic Participation: An Evidence-Based Subject Review , 2008, Clinical journal of sport medicine : official journal of the Canadian Academy of Sport Medicine.

[27]  Nicholas F. Polys,et al.  A virtual look at Epstein-Barr virus infection: simulation mechanism. , 2008, Journal of theoretical biology.

[28]  S. Tyring,et al.  Herpesvirus prevalence and viral load in healthy blood donors by quantitative real‐time polymerase chain reaction , 2008, Transfusion.

[29]  S. Kojima,et al.  Clinical and virological characteristics of 15 patients with chronic active Epstein-Barr virus infection treated with hematopoietic stem cell transplantation. , 2008, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[30]  K. Ohshima,et al.  Proposed categorization of pathological states of EBV‐associated T/natural killer‐cell lymphoproliferative disorder (LPD) in children and young adults: Overlap with chronic active EBV infection and infantile fulminant EBV T‐LPD , 2008, Pathology international.

[31]  L. Lanier.  Evolutionary struggles between NK cells and viruses , 2008, Nature Reviews Immunology.

[32]  M. Smyth,et al.  The Early Kinetics of Cytomegalovirus-Specific CD8+ T-Cell Responses Are Not Affected by Antigen Load or the Absence of Perforin or Gamma Interferon , 2008, Journal of Virology.

[33]  B. Gruhn,et al.  Monitoring of Epstein‐Barr virus load after hematopoietic stem cell transplantation for early intervention in post‐transplant lymphoproliferative disease , 2008, Journal of medical virology.

[34]  T. Greenough,et al.  On the dynamics of acute EBV infection and the pathogenesis of infectious mononucleosis. , 2008, Blood.

[35]  M. Moutschen,et al.  Recombinant gp350 vaccine for infectious mononucleosis: a phase 2, randomized, double-blind, placebo-controlled trial to evaluate the safety, immunogenicity, and efficacy of an Epstein-Barr virus vaccine in healthy young adults. , 2007, The Journal of infectious diseases.

[36]  H. Balfour.  Epstein-Barr virus vaccine for the prevention of infectious mononucleosis--and what else? , 2007, The Journal of infectious diseases.

[37]  Andreas Suhrbier,et al.  Phase I Trial of a CD8+ T-Cell Peptide Epitope-Based Vaccine for Infectious Mononucleosis , 2007, Journal of Virology.

[38]  M. Nikiforova,et al.  Multicenter Comparison of Different Real-Time PCR Assays for Quantitative Detection of Epstein-Barr Virus , 2007, Journal of Clinical Microbiology.

[39]  H. Balfour.  Clinical, Viral and Antibody Kinetics during Infectious Mononucleosis (IM) , 2007 .

[40]  A. Swerdlow,et al.  Allogeneic cytotoxic T-cell therapy for EBV-positive posttransplantation lymphoproliferative disease: results of a phase 2 multicenter clinical trial. , 2007, Blood.

[41]  D. Walls,et al.  Manipulation of the Toll-Like Receptor 7 Signaling Pathway by Epstein-Barr Virus , 2007, Journal of Virology.

[42]  J. Seigneurin,et al.  Real-time quantitative PCR for assessment of antiviral drug effects against Epstein-Barr virus replication and EBV late mRNA expression. , 2007, Journal of virological methods.

[43]  L. Corey,et al.  Adolescents Are More Likely to Develop Posttransplant Lymphoproliferative Disorder After Primary Epstein-Barr Virus Infection Than Younger Renal Transplant Recipients , 2007, Transplantation.

[44]  Gary Dubin,et al.  Phase I/II studies to evaluate safety and immunogenicity of a recombinant gp350 Epstein-Barr virus vaccine in healthy adults. , 2007, Vaccine.

[45]  D. Tough,et al.  In vivo kinetics of human natural killer cells: the effects of ageing and acute and chronic viral infection , 2007, Immunology.

[46]  M. Diamond,et al.  Herpesvirus latency confers symbiotic protection from bacterial infection , 2007, Nature.

[47]  H. Balfour,et al.  A virologic pilot study of valacyclovir in infectious mononucleosis. , 2007, Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology.

[48]  H. Myrmel,et al.  Prevalence of primary versus reactivated Epstein-Barr virus infection in patients with VCA IgG-, VCA IgM- and EBNA-1-antibodies and suspected infectious mononucleosis. , 2007, Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology.

[49]  A. Rickinson,et al.  Cellular responses to viral infection in humans: lessons from Epstein-Barr virus. , 2007, Annual review of immunology.

[50]  J. Palefsky,et al.  Characterization of the Epstein-Barr virus glycoprotein BMRF-2. , 2007, Virology.

[51]  A. Swerdlow,et al.  A study of risk factors for acquisition of Epstein-Barr virus and its subtypes. , 2007, The Journal of infectious diseases.

[52]  V. Krishnamurthi.  Meta-Analysis: The Efficacy of Strategies to Prevent Organ Disease by Cytomegalovirus in Solid Organ Transplant Recipients , 2006 .

[53]  Sumita Bhaduri-McIntosh,et al.  Cells lytically infected with Epstein-Barr virus are detected and separable by immunoglobulins from EBV-seropositive individuals. , 2006, Journal of virological methods.

[54]  L. Hutt-Fletcher,et al.  Antibodies to gp350/220 Enhance the Ability of Epstein-Barr Virus To Infect Epithelial Cells , 2006, Journal of Virology.

[55]  R. Sheeler,et al.  Clinical inquiries. What test is the best for diagnosing infectious mononucleosis? , 2006, The Journal of family practice.

[56]  A. Swerdlow,et al.  A cohort study among university students: identification of risk factors for Epstein-Barr virus seroconversion and infectious mononucleosis. , 2006, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[57]  H. Kimura.  Pathogenesis of chronic active Epstein‐Barr virus infection: Is this an infectious disease, lymphoproliferative disorder, or immunodeficiency? , 2006, Reviews in medical virology.

[58]  Y. Naumov,et al.  Memory of mice and men: CD8+ T‐cell cross‐reactivity and heterologous immunity , 2006, Immunological reviews.

[59]  A. Humar,et al.  A Randomized Trial of Ganciclovir versus Ganciclovir Plus Immune Globulin for Prophylaxis Against Epstein-Barr Virus Related Posttransplant Lymphoproliferative Disorder , 2006, Transplantation.

[60]  K. Olthoff,et al.  Treatment of PTLD with Rituximab or Chemotherapy , 2006, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[61]  B. Candy,et al.  Steroids for symptom control in infectious mononucleosis. , 2006, The Cochrane database of systematic reviews.

[62]  Richard C Brundage,et al.  A prospective clinical study of Epstein-Barr virus and host interactions during acute infectious mononucleosis. , 2005, The Journal of infectious diseases.

[63]  R. Ambinder,et al.  Mononucleosis in the laboratory. , 2005, The Journal of infectious diseases.

[64]  T. Doerr,et al.  Infectious mononucleosis and corticosteroids: management practices and outcomes. , 2005, Archives of otolaryngology--head & neck surgery.

[65]  H. Kanegane,et al.  Proposed guidelines for diagnosing chronic active Epstein‐Barr virus infection , 2005, American journal of hematology.

[66]  R. Egeler,et al.  Allogeneic stem cell transplantation in X-linked lymphoproliferative disease: two cases in one family and review of the literature , 2005, Bone Marrow Transplantation.

[67]  A. Webster,et al.  Antiviral medications to prevent cytomegalovirus disease and early death in recipients of solid-organ transplants: a systematic review of randomised controlled trials , 2005, The Lancet.

[68]  P. Farrell,et al.  Reactivation of Epstein‐Barr virus from latency , 2005, Reviews in medical virology.

[69]  A. Swerdlow,et al.  The immune response to primary EBV infection: a role for natural killer cells , 2005, British journal of haematology.

[70]  O. Genoulaz,et al.  Long-term shedding of infectious epstein-barr virus after infectious mononucleosis. , 2005, The Journal of infectious diseases.

[71]  S. Tangye,et al.  Regulation of NKT cell development by SAP, the protein defective in XLP , 2005, Nature Medicine.

[72]  E. Morra,et al.  Significance of Epstein-Barr virus (EBV) load and Interleukin-10 in post-transplant lymphoproliferative disorders , 2005, Leukemia & lymphoma.

[73]  L. Silverman,et al.  Treatment of primary Epstein-Barr virus infection in patients with X-linked lymphoproliferative disease using B-cell-directed therapy. , 2004, Blood.

[74]  A. Kudoh,et al.  Latent and lytic Epstein‐Barr virus replication strategies , 2005, Reviews in medical virology.

[75]  D. Pegtel,et al.  Epstein-Barr Virus Infection in Ex Vivo Tonsil Epithelial Cell Cultures of Asymptomatic Carriers , 2004, Journal of Virology.

[76]  L. Young,et al.  Epstein–Barr virus: 40 years on , 2004, Nature Reviews Cancer.

[77]  H. Heslop,et al.  Cellular therapy of Epstein-Barr-virus-associated post-transplant lymphoproliferative disease. , 2004, Best practice & research. Clinical haematology.

[78]  F. Pereira,et al.  Prevalence of Epstein-Barr virus antibodies in healthy children and adolescents in Vitória, State of Espírito Santo, Brazil. , 2004, Revista da Sociedade Brasileira de Medicina Tropical.

[79]  B. Fisher,et al.  False-Positive Result Provided by Rapid Heterophile Antibody Test in a Case of Acute Infection with Hepatitis E Virus , 2004, Journal of Clinical Microbiology.

[80]  R. D. Hess.  Routine Epstein-Barr Virus Diagnostics from the Laboratory Perspective: Still Challenging after 35 Years , 2004, Journal of Clinical Microbiology.

[81]  P. Auwaerter.  Infectious mononucleosis: return to play. , 2004, Clinics in sports medicine.

[82]  E. De Clercq,et al.  Evaluation of antiviral activity against human herpesvirus 8 (HHV-8) and Epstein-Barr virus (EBV) by a quantitative real-time PCR assay. , 2004, Antiviral research.

[83]  D. Thorley-Lawson,et al.  Acute Infection with Epstein-Barr Virus Targets and Overwhelms the Peripheral Memory B-Cell Compartment with Resting, Latently Infected Cells , 2004, Journal of Virology.

[84]  K. Karube,et al.  Clinicopathological states of Epstein-Barr virus-associated T/NK-cell lymphoproliferative disorders (severe chronic active EBV infection) of children and young adults. , 2004, International journal of oncology.

[85]  D. Thorley-Lawson,et al.  Persistence of the Epstein-Barr virus and the origins of associated lymphomas. , 2004, The New England journal of medicine.

[86]  M. Corsi,et al.  High Th1-type cytokine serum levels in patients with infectious mononucleosis. , 2004, Acta virologica.

[87]  S. Webber,et al.  Measurement of Epstein-Barr Virus DNA Loads in Whole Blood and Plasma by TaqMan PCR and in Peripheral Blood Lymphocytes by Competitive PCR , 2003, Journal of Clinical Microbiology.

[88]  Manfred S. Green,et al.  Clinical and laboratory presentation of EBV positive infectious mononucleosis in young adults , 2003, Epidemiology and Infection.

[89]  R. Pitetti,et al.  Clinical evaluation of a quantitative real time polymerase chain reaction assay for diagnosis of primary Epstein-Barr virus infection in children , 2003, The Pediatric infectious disease journal.

[90]  S. Knuutila,et al.  High incidence of PTLD after non-T-cell-depleted allogeneic haematopoietic stem cell transplantation as a consequence of intensive immunosuppressive treatment , 2003, Bone Marrow Transplantation.

[91]  Jung‐Chung Lin.  Mechanism of action of glycyrrhizic acid in inhibition of Epstein-Barr virus replication in vitro. , 2003, Antiviral research.

[92]  S. Swaminathan.  Molecular biology of Epstein-Barr virus and Kaposi's sarcoma-associated herpesvirus. , 2003, Seminars in hematology.

[93]  M. Somasundaran,et al.  Differential Kinetics and Specificity of EBV-Specific CD4+ and CD8+ T Cells During Primary Infection1 , 2003, The Journal of Immunology.

[94]  D. Porter,et al.  Post-transplant lymphoproliferative disorder: a review , 2003, Bone Marrow Transplantation.

[95]  J. Palefsky,et al.  Epstein-Barr virus infection of polarized tongue and nasopharyngeal epithelial cells , 2003, Nature Medicine.

[96]  J. Orange.  Human natural killer cell deficiencies and susceptibility to infection. , 2002, Microbes and infection.

[97]  W. Snowden,et al.  Valacyclovir for herpes simplex virus infection: long-term safety and sustained efficacy after 20 years' experience with acyclovir. , 2002, Journal of Infectious Diseases.

[98]  A. Swerdlow,et al.  Sexual history and Epstein-Barr virus infection. , 2002, The Journal of infectious diseases.

[99]  L. Hutt-Fletcher,et al.  Alternate replication in B cells and epithelial cells switches tropism of Epstein–Barr virus , 2002, Nature Medicine.

[100]  A. Rickinson.  Epstein-Barr virus. , 2001, Virus research.

[101]  T. Rea,et al.  A systematic study of Epstein-Barr virus serologic assays following acute infection. , 2002, American journal of clinical pathology.

[102]  S. L. Silins,et al.  Asymptomatic primary Epstein-Barr virus infection occurs in the absence of blood T-cell repertoire perturbations despite high levels of systemic viral load. , 2001, Blood.

[103]  P. Bucsky,et al.  PATIENTS AT RISK FOR DEVELOPMENT OF POSTTRANSPLANT LYMPHOPROLIFERATIVE DISORDER: PLASMA VERSUS PERIPHERAL BLOOD MONONUCLEAR CELLS AS MATERIAL FOR QUANTIFICATION OF EPSTEIN-BARR VIRAL LOAD BY USING REAL-TIME QUANTITATIVE POLYMERASE CHAIN REACTION1,2 , 2001, Transplantation.

[104]  Y. Sakiyama,et al.  Differential cellular targets of Epstein-Barr virus (EBV) infection between acute EBV-associated hemophagocytic lymphohistiocytosis and chronic active EBV infection. , 2001, Blood.

[105]  M. Okano.  Epstein-Barr virus in patients with immunodeficiency disorders. , 2001, Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie.

[106]  B. van der Holt,et al.  Epstein-Barr virus (EBV) reactivation is a frequent event after allogeneic stem cell transplantation (SCT) and quantitatively predicts EBV-lymphoproliferative disease following T-cell--depleted SCT. , 2001, Blood.

[107]  L. Notarangelo,et al.  NTB-A [correction of GNTB-A], a novel SH2D1A-associated surface molecule contributing to the inability of natural killer cells to kill Epstein-Barr virus-infected B cells in X-linked lymphoproliferative disease. , 2001, The Journal of experimental medicine.

[108]  H. Kanegane,et al.  Clinical and virologic characteristics of chronic active Epstein-Barr virus infection. , 2001, Blood.

[109]  G. Tosato,et al.  Diagnosis of atypical cases of infectious mononucleosis. , 2001, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[110]  T. Rea,et al.  Prospective study of the natural history of infectious mononucleosis caused by Epstein-Barr virus. , 2001, The Journal of the American Board of Family Practice.

[111]  J. Reyes,et al.  Epstein–Barr virus load monitoring: its role in the prevention and management of post‐transplant lymphoproliferative disease , 2001, Transplant infectious disease : an official journal of the Transplantation Society.

[112]  B. Dutia,et al.  Murine gammaherpesvirus-68 infection causes multi-organ fibrosis and alters leukocyte trafficking in interferon-gamma receptor knockout mice. , 2001, The American journal of pathology.

[113]  W. Hammerschmidt,et al.  Molecular virology of Epstein-Barr virus. , 2001, Philosophical transactions of the Royal Society of London. Series B, Biological sciences.

[114]  B. Somer,et al.  REDUCTION IN IMMUNOSUPPRESSION AS INITIAL THERAPY FOR POSTTRANSPLANT LYMPHOPROLIFERATIVE DISORDER: ANALYSIS OF PROGNOSTIC VARIABLES AND LONG-TERM FOLLOW-UP OF 42 ADULT PATIENTS1 , 2001, Transplantation.

[115]  Jaap M Middeldorp,et al.  Toward Standardization of Epstein-Barr Virus DNA Load Monitoring: Unfractionated Whole Blood as Preferred Clinical Specimen , 2001, Journal of Clinical Microbiology.

[116]  M. Gulley.  Molecular diagnosis of Epstein-Barr virus-related diseases. , 2001, The Journal of molecular diagnostics : JMD.

[117]  P. Engel,et al.  X-linked lymphoproliferative disease: a progressive immunodeficiency. , 2001, Annual review of immunology.

[118]  R. Longnecker,et al.  Epstein-Barr virus entry into cells. , 2000, Virology.

[119]  L. Notarangelo,et al.  X-Linked Lymphoproliferative Disease 2b4 Molecules Displaying Inhibitory Rather than Activating Function Are Responsible for the Inability of Natural Killer Cells to Kill Epstein-Barr Virus–Infected Cells , 2000 .

[120]  H. Jenson.  Acute complications of Epstein-Barr virus infectious mononucleosis , 2000, Current opinion in pediatrics.

[121]  F. Baldanti,et al.  High Levels of Epstein-Barr Virus DNA in Blood of Solid-Organ Transplant Recipients and Their Value in Predicting Posttransplant Lymphoproliferative Disorders , 2000, Journal of Clinical Microbiology.

[122]  J. Spivak,et al.  Commentary on and reprint of Sprunt TP, Evans FA, Mononuclear leukocytosis in reaction to acute infections (“infectious mononucleosis”), in Bulletin of the Johns Hopkins Hospital (1920) 31:410–417 , 2000 .

[123]  E. Kieff,et al.  Epstein-barr virus-induced posttransplant lymphoproliferative disorders , 1999 .

[124]  V. Zacny,et al.  Inhibition of Epstein-Barr Virus Replication by a Benzimidazole l-Riboside: Novel Antiviral Mechanism of 5,6-Dichloro-2-(Isopropylamino)-1-β-l-Ribofuranosyl-1H-Benzimidazole , 1999, Journal of Virology.

[125]  Richard E. Slaughter,et al.  Activation and adoptive transfer of Epstein-Barr virus-specific cytotoxic T cells in solid organ transplant patients with posttransplant lymphoproliferative disease. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[126]  H. Wakiguchi,et al.  Persistently high Epstein-Barr virus (EBV) loads in peripheral blood lymphocytes from patients with chronic active EBV infection. , 1999, The Journal of infectious diseases.

[127]  R. Spaete,et al.  Expression of Epstein-Barr virus gp350 as a single chain glycoprotein for an EBV subunit vaccine. , 1999, Vaccine.

[128]  P. Auwaerter.  Infectious mononucleosis in middle age. , 1999, JAMA.

[129]  T. Sculley,et al.  A-type and B-type Epstein-Barr virus differ in their ability to spontaneously enter the lytic cycle. , 1999, The Journal of general virology.

[130]  H. Balfour.  Drug therapy : Antiviral drugs , 1999 .

[131]  E. Kieff,et al.  Epstein-Barr virus-induced posttransplant lymphoproliferative disorders. ASTS/ASTP EBV-PTLD Task Force and The Mayo Clinic Organized International Consensus Development Meeting. , 1999, Transplantation.

[132]  E. Snyder,et al.  Inactivating mutations in an SH2 domain-encoding gene in X-linked lymphoproliferative syndrome. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[133]  D. Sage,et al.  The Epstein-Barr Virus Thymidine Kinase Does Not Phosphorylate Ganciclovir or Acyclovir and Demonstrates a Narrow Substrate Specificity Compared to the Herpes Simplex Virus Type 1 Thymidine Kinase , 1998, Antimicrobial Agents and Chemotherapy.

[134]  D. Allen,et al.  The X-linked lymphoproliferative-disease gene product SAP regulates signals induced through the co-receptor SLAM , 1998, Nature.

[135]  Jack R. Davis,et al.  Host response to EBV infection in X-linked lymphoproliferative disease results from mutations in an SH2-domain encoding gene , 1998, Nature Genetics.

[136]  D. Thorley-Lawson,et al.  EBV persistence in memory B cells in vivo. , 1998, Immunity.

[137]  E. De Clercq,et al.  Inhibitory Effects of Novel Nucleoside and Nucleotide Analogues on Epstein—Barr Virus Replication , 1998, Antiviral chemistry & chemotherapy.

[138]  P. Thall,et al.  Serum cytokine levels in infectious mononucleosis at diagnosis and convalescence. , 1998, Leukemia & lymphoma.

[139]  H. Kanegane,et al.  A Syndrome of Peripheral Blood T-Cell Infection With Epstein-Barr Virus ( EBV ) Followed by EBV – Positive T-Cell Lymphoma , 1998 .

[140]  L. Frappier,et al.  Human CD8+ T cell responses to EBV EBNA1: HLA class I presentation of the (Gly-Ala)-containing protein requires exogenous processing. , 1997, Immunity.

[141]  J. Saffitz,et al.  Murine gamma-herpesvirus 68 causes severe large-vessel arteritis in mice lacking interferon-gamma responsiveness: a new model for virus-induced vascular disease. , 1997, Nature medicine.

[142]  A. Rickinson,et al.  Acyclovir and prednisolone treatment of acute infectious mononucleosis: a multicenter, double-blind, placebo-controlled study. , 1996, The Journal of infectious diseases.

[143]  Eichner Er.  Infectious mononucleosis: recognizing the condition, 'reactivating' the patient. , 1996 .

[144]  E. Kieff.  Epstein-Barr virus and its replication , 1996 .

[145]  A. Sinicco,et al.  Serum cytokine profiles in acute primary HIV-1 infection and in infectious mononucleosis. , 1996, Clinical immunology and immunopathology.

[146]  M. Warwick,et al.  Decreased levels of circulating IFN-alpha and increased sCD23 in patients with acute infectious mononucleosis. , 1996, Viral immunology.

[147]  G. Delage,et al.  Epstein-Barr virus transmission from a blood donor to an organ transplant recipient with recovery of the same virus strain from the recipient's blood and oropharynx. , 1996, Blood.

[148]  G. Tosato,et al.  Human and viral interleukin-10 in acute Epstein-Barr virus-induced infectious mononucleosis. , 1995, The Journal of infectious diseases.

[149]  M. Hornef,et al.  Cytokine production in a whole-blood assay after Epstein-Barr virus infection in vivo , 1995, Clinical and diagnostic laboratory immunology.

[150]  C. Chu,et al.  First EBV vaccine trial in humans using recombinant vaccinia virus expressing the major membrane antigen. , 1995, Developments in biological standardization.

[151]  T. Ko,et al.  Infectious Mononucleosis in Children , 1994 .

[152]  L. Dewitt,et al.  Neurologic complications of infectious mononucleosis. , 1994, Pediatric neurology.

[153]  C. Alfieri,et al.  Direct correlation between the load of Epstein-Barr virus-infected lymphocytes in the peripheral blood of pediatric transplant patients and risk of lymphoproliferative disease. , 1994, Blood.

[154]  H. Stein,et al.  Patterns of cytokine gene expression in infectious mononucleosis. , 1994, Blood.

[155]  D. Cederberg,et al.  Pharmacokinetics of the acyclovir pro‐drug valaciclovir after escalating single‐and multiple‐dose administration to normal volunteers , 1993, Clinical pharmacology and therapeutics.

[156]  Carlos Lopez,et al.  Human Herpesviruses: List of contributors , 2007 .

[157]  G. Reibnegger,et al.  Serum concentrations of interferon gamma, interleukin-6 and neopterin in patients with infectious mononucleosis and other Epstein-Barr virus-related lymphoproliferative diseases , 1993, Infection.

[158]  E. Kieff,et al.  Localization of Epstein-Barr virus cytotoxic T cell epitopes using recombinant vaccinia: implications for vaccine development , 1992, The Journal of experimental medicine.

[159]  P. Forsberg,et al.  Serum levels of lymphokines and soluble cellular receptors in primary Epstein-Barr virus infection and in patients with chronic fatigue syndrome. , 1992, The Journal of infectious diseases.

[160]  G. Fleisher,et al.  Lack of effect of peroral acyclovir for the treatment of acute infectious mononucleosis. , 1991, The Journal of infectious diseases.

[161]  R. Baumgarten,et al.  [Splenic rupture in infectious mononucleosis]. , 1991, Zeitschrift fur arztliche Fortbildung.

[162]  Y. Sakiyama,et al.  Severe chronic active Epstein-Barr virus infection syndrome , 1991, Clinical Microbiology Reviews.

[163]  E. Kieff,et al.  Epstein-Barr virus types 1 and 2 differ in their EBNA-3A, EBNA-3B, and EBNA-3C genes , 1990, Journal of virology.

[164]  B. Storer,et al.  Biological and Clinical Effects of the Combination of β- and γ-Interferons Administered as a 5-Day Continuous Infusion , 1990 .

[165]  T. Mosmann,et al.  Homology of cytokine synthesis inhibitory factor (IL-10) to the Epstein-Barr virus gene BCRFI. , 1990, Science.

[166]  R. Chang,et al.  A prospective study of primary Epstein-Barr virus infections among university students in Hong Kong. , 1990, The American journal of tropical medicine and hygiene.

[167]  S. Burrows,et al.  An Epstein-Barr virus-specific cytotoxic T cell epitope in EBV nuclear antigen 3 (EBNA 3) , 1990, The Journal of experimental medicine.

[168]  B. Storer,et al.  Biological and clinical effects of the combination of beta- and gamma-interferons administered as a 5-day continuous infusion. , 1990, Cancer research.

[169]  Hiroshi Sato,et al.  Differences in the ability of cells to fuse are mediated by strains of epstein‐barr virus , 1989, The Laryngoscope.

[170]  K. Hirai,et al.  CD3-negative lymphoproliferative disease of granular lymphocytes containing Epstein-Barr viral DNA. , 1989, The Journal of clinical investigation.

[171]  I. Ernberg,et al.  Eradication of Epstein-Barr virus by allogeneic bone marrow transplantation: implications for sites of viral latency. , 1988, Proceedings of the National Academy of Sciences of the United States of America.

[172]  R. Robinson,et al.  Abdominal Complications Of Infectious Mononucleosis , 1988, The Journal of the American Board of Family Medicine.

[173]  Jack R. Davis,et al.  Epstein-Barr virus and human diseases: recent advances in diagnosis , 1988, Clinical Microbiology Reviews.

[174]  I. Kobayashi,et al.  Epstein-Barr virus genome-positive T lymphocytes in a boy with chronic active EBV infection associated with Kawasaki-like disease , 1988, Nature.

[175]  B. Burke,et al.  Epstein-Barr virus associated B cell lymphoproliferative disorders following bone marrow transplantation. , 1988, Blood.

[176]  James F. Jones,et al.  T-cell lymphomas containing Epstein-Barr viral DNA in patients with chronic Epstein-Barr virus infections. , 1988, The New England journal of medicine.

[177]  D. Nelson,et al.  Activated lymphocytes during acute Epstein-Barr virus infection. , 1987, Journal of immunology.

[178]  L. Young,et al.  Influence of the Epstein-Barr virus nuclear antigen EBNA 2 on the growth phenotype of virus-transformed B cells , 1987, Journal of virology.

[179]  J. Giesecke,et al.  Acyclovir treatment in infectious mononucleosis: A clinical and virological study , 1987, Infection.

[180]  G. Lenoir,et al.  Geographical prevalence of two types of Epstein-Barr virus. , 1986, Virology.

[181]  M. Epstein,et al.  Not all potently neutralizing, vaccine-induced antibodies to Epstein-Barr virus ensure protection of susceptible experimental animals. , 1986, Clinical and experimental immunology.

[182]  I. Ernberg,et al.  Effect of acyclovir on infectious mononucleosis: a double-blind, placebo-controlled study. , 1986, The Journal of infectious diseases.

[183]  White Lr,et al.  Review of the clinical manifestations, laboratory findings, and complications of infectious mononucleosis. , 1985 .

[184]  E. Kieff,et al.  Biochemistry of latent Epstein-Barr virus infection and associated cell growth transformation. , 1985, IARC scientific publications.

[185]  L. R. White,et al.  Review of the clinical manifestations, laboratory findings, and complications of infectious mononucleosis. , 1985, Wisconsin medical journal.

[186]  C. Alfieri,et al.  Lytic, nontransforming Epstein-Barr virus (EBV) from a patient with chronic active EBV infection. , 1984, Canadian Medical Association journal.

[187]  J. Pagano,et al.  Prolonged inhibitory effect of 9-(1,3-dihydroxy-2-propoxymethyl)guanine against replication of Epstein-Barr virus , 1984, Journal of virology.

[188]  H. Blomgren,et al.  Virologic, immunologic, and clinical observations on a patient during the incubation, acute, and convalescent phases of infectious mononucleosis. , 1984, Clinical immunology and immunopathology.

[189]  W. Henle,et al.  Fatal illness in a 2-week-old infant: diagnosis by detection of Epstein-Barr virus genomes from a lymph node biopsy. , 1983, The Journal of pediatrics.

[190]  W. Henle,et al.  Infectious Mononucleosis in Patients Aged 40 to 72 Years: Report of 27 Cases, Including 3 Without Heterophil‐Antibody Responses , 1983, Medicine.

[191]  J. Pagano,et al.  Acyclovir and Epstein-Barr virus infection. , 1983, The Journal of antimicrobial chemotherapy.

[192]  E. Kieff,et al.  The biology and chemistry of Epstein-Barr virus. , 1982, The Journal of infectious diseases.

[193]  H. Cross,et al.  In utero Epstein-Barr virus (infectious mononucleosis) infection. , 1982, JAMA.

[194]  J. Najarian,et al.  Clinical spectrum of lymphoproliferative disorders in renal transplant recipients and evidence for the role of Epstein-Barr virus. , 1981, Cancer research.

[195]  H. Balfour,et al.  Clinical and laboratory evaluation of infants and children with Epstein-Barr virus-induced infectious mononucleosis: report of 32 patients (aged 10-48 months). , 1981, Blood.

[196]  R. Chang,et al.  RECURRENCE OF INFECTIOUS MONONUCLEOSIS , 1980, The Lancet.

[197]  W. Henle,et al.  Persistent falsely positive rapid tests for infectious mononucleosis. Report of five cases with four--six-year follow-up data. , 1979, American journal of clinical pathology.

[198]  S. Halstead,et al.  Incidence of infectious mononucleosis at the Universities of California and Hawaii. , 1979, The Journal of infectious diseases.

[199]  A. Evans.  Infectious mononucleosis and related syndromes , 1978, The American journal of the medical sciences.

[200]  H. Schaeffer,et al.  Selectivity of action of an antiherpetic agent, 9-(2-hydroxyethoxymethyl) guanine. , 1977, Proceedings of the National Academy of Sciences of the United States of America.

[201]  W. Henle,et al.  Infectious mononucleosis in children. Evaluation of Epstein-Barr virus-specific serological data. , 1977, JAMA.

[202]  G. Vawter,et al.  Hematopathology and Pathogenesis of the X-linked recessive lymphoproliferative syndrome. , 1977, The American journal of medicine.

[203]  J. Edwards,et al.  Measurement of heterophil antibody and antibodies to EB viral capsid antigen IgG and IgM in suspected cases of infectious mononucleosis. , 1976, Journal of clinical pathology.

[204]  C. Sumaya,et al.  Seroepidemiologic study of Epstein-Barr virus infections in a rural community. , 1975, The Journal of infectious diseases.

[205]  N. Day,et al.  Sero-epidemiology of the Epstein-Barr virus: preliminary analysis of an international study - a review. , 1975, IARC scientific publications.

[206]  C. M. Brooks,et al.  Infectious Mononucleosis at the United States Military Academy. A Prospective Study of a Single Class Over Four Years 1 , 1974, The Yale journal of biology and medicine.

[207]  J. Paul,et al.  THE PRESENCE OF HETEROPHILE ANTIBODIES IN INFECTIOUS MONONUCLEOSIS , 1932, The American journal of the medical sciences.

[208]  L. Elveback,et al.  Infectious mononucleosis in Rochester, Minnesota, 1950 through 1969. , 1973, American journal of epidemiology.

[209]  M. Epstein,et al.  The EB virus. , 1973, Annual review of microbiology.

[210]  Leard Se.  Seasonal incidence of infectious mononucleosis. , 1972 .

[211]  C. Heath,et al.  Infectious mononucleosis: epidemiologic patterns at United States colleges and universities. , 1972, American journal of epidemiology.

[212]  H. Balfour,et al.  Penicillin-related Exanthems in Infectious Mononucleosis Identical to Those Associated with Ampicillin , 1972, Clinical pediatrics.

[213]  S. Leard.  Seasonal incidence of infectious mononucleosis. , 1972, Journal of the American College Health Association.

[214]  A. Evans,et al.  Prospective studies of a group of Yale University freshmen. I. Occurrence of infectious mononucleosis. , 1971, The Journal of infectious diseases.

[215]  G. Klein,et al.  Relation between neutralization of Epstein-Barr virus and antibodies to cell-membrane antigens-induced by the virus. , 1970, Journal of the National Cancer Institute.

[216]  D. Lehane.  A seroepidemiologic study of infectious mononucleosis. The development of EB virus antibody in a military population. , 1970, JAMA.

[217]  R. Purcell,et al.  Association of EB-virus infection with the post-perfusion syndrome. , 1969, Lancet.

[218]  V. Diehl,et al.  Relation of Burkitt's tumor-associated herpes-ytpe virus to infectious mononucleosis. , 1968, Proceedings of the National Academy of Sciences of the United States of America.

[219]  B. Patel.  Skin rash with infectious mononucleosis and ampicillin. , 1967, Pediatrics.

[220]  M. Epstein,et al.  VIRUS PARTICLES IN CULTURED LYMPHOBLASTS FROM BURKITT'S LYMPHOMA. , 1964, Lancet.

[221]  R. Hoagland.  THE CLINICAL MANIFESTATIONS OF INFECTIOUS MONONUCLEOSIS A REPORT OF TWO HUNDRED CASES , 1960, The American journal of the medical sciences.

[222]  Hoagland Rj.  The transmission of infectious mononucleosis. , 1955 .

[223]  R. Hoagland,et al.  The transmission of infectious mononucleosis. , 1955, The American journal of the medical sciences.

[224]  J. Collee,et al.  Infectious mononucleosis. , 1956, The American journal of nursing.

[225]  A. Evans.  Further experimental attempts to transmit infectious mononucleosis to man. , 1950, The Journal of clinical investigation.

[226]  A. Evans,et al.  An Epidemiologic Study of Infectious Mononucleosis in a New England College , 1950 .

[227]  A. McKinlay.  INFECTIOUS MONONUCLEOSIS: PART I. CLINICAL ASPECTS , 1935 .

[228]  C. Mckinlay,et al.  ACUTE LYMPHADENOSIS COMPARED WITH ACUTE LYMPHATIC LEUKEMIA , 1923 .